TOP » 新型コロナウイルス 5類感染症移行に伴う弊社の対応について

About our response to the transition to the new coronavirus Class 5 infectious disease

Dear Sirs, We would like to express our sincere gratitude for your continued support.

We would like to express our deepest sympathies to all those affected by the new coronavirus (COVID-19) and those who have been affected by their lives.

 

The Minister of Health, Labour and Welfare informed us that it will be classified as a "Class 5 infectious disease" under the Infectious Diseases Act from May 8.

In accordance with the communication of the Ministry of Health, Labor and Welfare, we will respond in the same way as seasonal influenza. (There are exceptions depending on the case)

However, in order to further consider the prevention of the spread of infection, the Tokyo Sales Office will continue to work from home as follows.

Inquiries will be accepted from the telephone and e-mail addresses in the table below.

 

Notes

◆ Base Response

Sapporo Head Office

Business as usual

電話受付   :  011-598-7833 (受付時間:月~金曜日 10:00-16:00)

Mail     :  custom@edison-hw.co.jp

◆Tokyo Office

Responding by working from home

Mail     :  custom@edison-hw.co.jp

* It is possible to send a message from the head office to the person in charge, but it may take some time. Please note.

* It is also possible to accept from "Inquiry" at the top right of this site. (Files can also be attached)

 

◆ When visiting our office, we ask for your understanding and cooperation in the following contents.

  • If you have a fever, cold symptoms, or are worried about your physical condition, please refrain from visiting the office.
  • Wearing a mask is left to the discretion of the individual.
  • Seminars, meetings with customers, etc. may be handled online.

 

We will continue to strive to contain the spread of infection and implement measures based on government policy.

* The Ministry of Health, Labour and Welfare says, "If the scientific assumptions are different, such as the emergence of mutant strains that are significantly different in pathogenicity from the Omicron variant, we will immediately review our response."

 

that's all